Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma

References

• Global Cancer Observatory https://gco.iarc.fr/
   Google Scholar
• Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer Vol. 2018;118(1):9–16. pages. .
   PubMed Web of Science ®Google Scholar
• Dirk Schadendorf F, Stephen Hodi JD, Wolchok, et al., Pooled analysis of long-term survival data from phase ii and phase iii trials of ipilimumab in unresectable or metastatic melanoma. J clin oncol. 33(17): 1889–1894. 2015. .
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. .
   PubMed Web of Science ®Google Scholar
• Caroline Robert, Georgina VL, Victoria Atkinson, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J clin oncol. 2020;38(33):3937–3946. .
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet Lond Engl. 384(9948): 1109–1117. 2014. .
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Ribas A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582-588.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Antoni Ribas, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun;25;372(26):2521-2532.
   Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 July 22;20(9):1239–1251.
   Web of Science ®Google Scholar
• James Larkin F, Stephen Hodi JD, Wolchok, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Wolchok JD, et al., Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 381(16): 1535–1546. 2019. .
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al., Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 371(20): 1867–1876. 2014.
   PubMed Web of Science ®Google Scholar
• Dreno B, Ascierto PA, McArthur GA, et al. Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF V600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. J clin oncol. 2018 May 20;36(15_suppl):9522.
   Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al., Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 386(9992): 444–451. 2015. .
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15;381(7):626–636. . Epub 2019 Jun 4.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Schadendorf D et al.. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30–39. . Epub 2014 Nov 16.
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019 Aug 15;381(7):626–636. . Epub 2019 Jun 4.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al., Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open label, randomised phase 3 trial. Lancet Oncol. 19(5): 603–615. 2018. .
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dummer R, Robert C, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. Eur J Cancer. 2020 Feb;126:33–44.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DCTLA. 4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.
   PubMed Web of Science ®Google Scholar
• Stamper CC, Zhang Y, Tobin JF. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410(6828):608–611.
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–603. .
   PubMed Web of Science ®Google Scholar
• Esensten JH, Helou YA, Chopra G, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973–988. .
   PubMed Web of Science ®Google Scholar
• Wolchok JD, HodiF. S, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291(1):1–13. 1291. .
   PubMedGoogle Scholar
• Carlino MS, Menzies AM, Atkinson V, et al. Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 October 1;26(19):5086–5091. 19.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob J, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European organisation for research and treatment of cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019 Sep; ;119::1–10.
   PubMed Web of Science ®Google Scholar
• Weber J, Del Vecchio M, Ascierto PA, et al. Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. Ann Oncol. 2020;31(suppl_4):S672–S7.
   Google Scholar
• Eggermont AMM, Blank CU, Robert C, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
   Google Scholar
• Eggermont AMM, Blank CU, Robert C, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Announces Update on CheckMate-. 915 for Opdivo (nivolumab) plus yervoy (ipilimumab) versus opdivo alone in patients with resected high-risk melanoma and PD-L1 <%. bms press release; 2020.
   Google Scholar
• Dummer R, Hauschild A, Schadendorf D, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020 Sep 2;383(12):1139–1148.
   PubMed Web of Science ®Google Scholar
• Maio M, Lewis K, Schadendorf D, et al. Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):510–520. .
   PubMed Web of Science ®Google Scholar
• Dreno B, Ascierto PA, McArthur GA, et al. Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. J Clin Oncol. 2018;36(15_suppl):9522. .
   Google Scholar
• Robert C, Grob JJ, Long GV et all. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626–636.
   Google Scholar
• Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249–256. .
   PubMed Web of Science ®Google Scholar
• Dummer R, Schadendorf D, Flaherty K, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435–445.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–2334. .
   PubMed Web of Science ®Google Scholar
• Zimmer L, Susmitha Apuri NI. Khushalani et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 April;75:47–55. Pages. .
   PubMed Web of Science ®Google Scholar
• Baron K, Moser JC, Hyngstrom JR, et al. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract. 2020 May;107815522092471. 10.1177/1078155220924719
   PubMed Web of Science ®Google Scholar
• Ines Pires Da Silva, Tasnia Ahmed, Georgina V, et al. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. J clin oncol. 2020 May 20;38(15_suppl).
   Web of Science ®Google Scholar
• Olson D, Luke JJ, Poklepovic AS, et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. Journal of Clinical Oncology. 2020;38:15_suppl,10004-10004.
   Google Scholar
• Atkins MB, Kudchadkar RR, Sosman JA, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J clin oncol. 2014 May 20;32(15_suppl):9001.
   Google Scholar
• Rutkowski P, Felip E, Kowalski D, et al. Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: updated phase I/II study results. Journal of Clinical Oncology. 2019;37:8_suppl, 31-31.
   Google Scholar
• Tjulandin S, Fedyanin M, Moiseenko V, et al. Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma. Ann Oncol. 2019;30:xi44.
   Google Scholar
• Ribas A, Hodi FS, Wolchok J, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 4;368(14):1365–1366.
   PubMed Web of Science ®Google Scholar
• Minor DR, Puzanov I, Hoos A, et al. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015;28(5):611–612. Sep;. .
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Haydu LE, Long GV, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014 Mar 1;192(5):2505–2513.
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15;19(2):40–393.
   Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 1;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Lawrence D, et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF mutant advanced melanoma. Ann Oncol. 2017;28(mdx377):003. .
   Google Scholar
• Ascierto PA, Ferrucci PF, Stephens R, et al. KEYNOTE-022 Part 3: phase 2 randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Ann Oncol. 2018;29:442–466.
   Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Ascierto PA, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Jun 13;395(10240):1835–1844. Erratum in: Lancet. 2020 Aug 15;396(10249):466.
   PubMed Web of Science ®Google Scholar
• Ribas A, Butler M, Gordon MS, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33(15_suppl):3003. .
   Web of Science ®Google Scholar
• Burton RN, Amaria IC, Tawbi HA Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): a single center phase II study. Ann Oncol Volume30, Supplement 5, October 2019, Pages 534–v535
   Web of Science ®Google Scholar
• Miller WH, Kim TM, Lee CB, et al. Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): updated safety and clinical activity. J Clin Oncol. 2017;35(15_suppl):3057. .
   Google Scholar
• Long GV, Lebbe C, Dummer R. The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. J clin oncol. 2020 May 20;38(15_suppl):10028. .
   Web of Science ®Google Scholar
• Nathan P, Dummer R, Schadendorf D. Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: results from the randomized part 3 of the phase III COMBI-i trial. Ann Oncol. 2020;31(suppl_4):S1142–S1215.
   Google Scholar
• Dummer R, Biette K, Long GV, et al. Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. J clin oncol. 2020 May;38(15_suppl):10034. .
   Web of Science ®Google Scholar
• Wang Y, Deng W, Nan L, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Thomas L, Robert C, et al. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. J clin oncol. 2011;29(18_suppl):e809-11. , Issue. .
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Ascierto PA, Maio M, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012 Sep;13(9):879–886. .
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Hurwitz ME, Bernatchez C, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R_-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711–721. .
   PubMed Web of Science ®Google Scholar
• Khushalani NI, Diab A, Long GV, et al. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: phase III PIVOT IO 001 study design. Future Oncologyvol. 16(28).
   Google Scholar
• Ascierto PA, Melero I, Hodi FS, et al., Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol. 35(15_suppl): 9520. 2017. .
   Web of Science ®Google Scholar
• Mitchell TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase i results from a multicenter, open-label phase i/ii trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223. .
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Mitchell TC, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised. Double-Blind StudyLancet Oncol. 2019 Aug;;20(8):1083–1097.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788. .
   PubMed Web of Science ®Google Scholar
• Andtbacka R, Ӧhrling K, Kaufman HL, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother Cancer volume7, Article number: 145 (2019) 1 10.1186/s40425-019-0623-z
   PubMedGoogle Scholar
• Ribas A, Dummer R, Long GV, et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 Immunotherapy. Cell. 2017 Sep 7;170(6):1109–1119.e10. Erratum in: Cell. 2018 Aug 9; 174( 4): 1031–1032. PMID: 28886381
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Andtbacka RHet al.Follow-up analysis of MASTERKEY-265 Phase 1b (ph1b) study of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (pembro) in patients (pts) with unresectable stage IIIB–IVM1c melanoma (MEL). Presented at: Society for Melanoma Research Congress 2018. Manchester, UK, October 24–27.
   Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–541. .
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Zarour HM, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–2186. .
   PubMed Web of Science ®Google Scholar
• Manieri NA, Chiang EY, Grogan JL, et al. Inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125(11):4053–4062. .
   PubMed Web of Science ®Google Scholar
• Mahnke K, Enk AHTIGIT. CD155 interactions in melanoma: a novel co-inhibitory pathway with potential for clinical intervention. J Investig Dermatol Vol. 2016 January;136:1.
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest. 2015;125(5):2046–2058. .
   PubMed Web of Science ®Google Scholar
• Kang SW, Lee SC, Park SH, et al. Anti-CD137 suppresses tumor growth by blocking reverse signaling by CD137. Ligand Cancer Res. 2017 Nov 1;77(21):5989–6000.
   PubMed Web of Science ®Google Scholar
• Zhang B. CD73 promotes tumor growth and metastasis. Oncoimmunology. 2012 Jan 1;1(1):67–70.
   PubMed Web of Science ®Google Scholar
• Morello S, Pinto A, Ascierto PA, et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017;15(1):244. , Article number:. .
   PubMedGoogle Scholar
• Siu LL, Burris H, Carvajal RD, et al. Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl): Abstract nr CT180
   Google Scholar
• Butler MO, Robert C, Diab A, et al. ILLUMINATE 301: a randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. J clin oncol. 37.15_suppl:, Issue.
   Web of Science ®Google Scholar
• Dougall WC, Aguilera AR, Smyth MJ. Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity Clinical & Translational Immunology. 2019;8(10):e1081.
   Google Scholar
• Rozeman EA, Sikorska KL, Van Thienen CU, et al. BlankPhase II study comparing pembrolizumab (PEM) with intermittent/short-term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra). Hannals of Oncology. 2018;29:_suppl, 8.
   Google Scholar
• Zak KM, Grudnik P, Holak TA, et al. Structural biology of the immune checkpoint receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure. 2017;25(8):1163–1174. .
   PubMed Web of Science ®Google Scholar
• Zhan MM, Hu XQ, Liao C, et al. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov Today. 2016;21(6):1027–1036. .
   PubMed Web of Science ®Google Scholar
• Toogood PL. Small molecule immuno-oncology therapeutic agents. Bioorg Med Chem Lett. 2018;28(3):319–329.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Braiteh F, Grilley-Olson JE. Assessment of subcutaneous vs intravenous administration of anti–PD-1 antibody PF-06801591 in patients with advanced solid tumors. A phase 1 dose-escalation trial. JAMA Oncol. 2019 Jul;5(7):999–1007.
   PubMed Web of Science ®Google Scholar
• Jansen YJL, Rozeman EA, Neyns B, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154–1161. .
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dummer R, Grimaldi AM, et al. SECOMBIT (sequential combo immuno and target therapy study): a three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I)/nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation. J clin oncol. 35.15_suppl:, Issue.
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03553836?term=NCT03553836&draw=2&rank=1
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT04099251?term=NCT04099251&draw=2&rank=1
   Google Scholar